Libang Capital Canada Ltd

Lipont Caus Capital is the international investment venture of the Libang Pharmaceutical Group. We are a major pharmaceutical producer in China with extensive advanced technology development and manufacturing capabilities, and seek innovative North American capabilities in the life sciences industries in which we can invest and work as strategic partners to develop and expand into global markets. We are interested in all aspects of personalized medicine, including emerging Stemcell science and therapies. We also seek innovative surgical procedures, including AI-enabled diagnostic and therapeutic robotic technologies, and sterilization/infection-control procedures and technologies. We are active in Japan and the Middle East, and welcome engagement with companies interested in broader Asian markets with innovative nutraceutical, manufacturing and materials processing capabilities. We shall use this page to share news about new and future corporate initiatives, and seek to engage actively with partners who share our interests and ambitions.